Qualified no-adjustment statementOfficial-label summariesMonitoring / toxicity / cautionsQualified no-adjustment statementsUnstudied ranges / evidence gaps
DailyMed / VERZENIO exact product label
Official label | Manually labeled selected summary
Product / population: VERZENIO oral tablets; product-specific breast-cancer indications and companion therapies. This renal summary does not choose an oncology regimen.
Renal measure: Cockcroft-Gault CrCl, mL/min; creatinine transport can complicate interpretation
Measure label: CrCl in mL/min. Read the exact source wording above.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: 7/2026
Retrieved: 2026-09-09
Exact DailyMed HTML label identity and selected named sections checked. A page update is not proof that renal instructions changed.
No raw SPL XML, original XML hash or separate Drugs@FDA revision-history review was performed.
1 documented source differences / product cautions
Not classified by finding typeOfficial-label summariesUnclassified / original material
Abiraterone acetate tablets (Yonsa) - selected U.S. label sections
Official label | Existing source category; topic coverage may be incomplete
Product / population: YONSA oral tablets only. Do not transfer dosing, food instructions or milligram equivalence from another abiraterone formulation.
Renal measure: Qualitative renal-impairment statement
Measure label: Measure not yet classified. Read the exact source wording above.
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Source dates and additional notes
Source revision: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
1 documented source differences / product cautions
Not classified by finding typeOfficial-label summariesUnclassified / original material
Abrocitinib tablets (Cibinqo, adults) - selected U.S. label sections
Official label | Existing source category; topic coverage may be incomplete
Product / population: Adult CIBINQO oral tablets. This entry does not supply a pediatric regimen.
Renal measure: MDRD eGFR; Table 1 reports mL/minute. Do not silently substitute Cockcroft-Gault CrCl.
Measure label: Measure not yet classified. Read the exact source wording above.
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Source dates and additional notes
Source revision: 6/2026
Retrieved: 2026-09-05
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
1 documented source differences / product cautions
Pharmacokinetic observation onlyOfficial-label summariesMonitoring / toxicity / cautionsUnstudied ranges / evidence gapsPharmacokinetic observations
DailyMed / ATTRUBY exact product label
Official label | Manually labeled selected summary
Product / population: ATTRUBY oral tablets for transthyretin amyloid cardiomyopathy. The selected finding is a biomarker/PK qualification, not a dialysis dosing protocol.
Renal measure: Indexed eGFR for observed biomarker changes; PK renal-stage boundaries not specified
Measure label: Indexed eGFR / GFR. Read the exact source wording above.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: 6/2026
Retrieved: 2026-09-09
Exact DailyMed HTML label identity and selected named sections checked. A page update is not proof that renal instructions changed.
No raw SPL XML, original XML hash or separate Drugs@FDA revision-history review was performed.
1 documented source differences / product cautions
Not classified by finding typeOfficial-label summariesUnclassified / original material
Adagrasib tablets (Krazati) - selected U.S. label sections
Official label | Existing source category; topic coverage may be incomplete
Product / population: KRAZATI oral tablets for the applicable adult oncology indication.
Renal measure: Cockcroft-Gault CrCl in mL/min
Measure label: Measure not yet classified. Read the exact source wording above.
Local label summary; independent clinical review pending. Not a two-source validated protocol.
Source dates and additional notes
Source revision: Revision not captured; retrieval date is not the revision date.
Retrieved: 2026-09-05
Selected renal sections only, not a complete monograph. Exact product, indication, patient population, renal method and all other contraindications/interactions remain controlling.
Second independent renal reference and clinician adjudication remain pending; no all-indication, dialysis or pediatric dose may be inferred from an omitted field.
No difference note is recorded here. This does not certify agreement.
Dose / interval guidanceOfficial-label summariesDose / interval guidanceMonitoring / toxicity / cautionsUnstudied ranges / evidence gaps
DailyMed / GILOTRIF exact product label
Official label | Manually labeled selected summary
Product / population: GILOTRIF tablets for its defined NSCLC indications. Baseline renal dosing and treatment-emergent toxicity modifications are distinct.
Renal measure: MDRD eGFR, mL/min/1.73 m2
Measure label: Indexed eGFR / GFR. Read the exact source wording above.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: 4/2022
Retrieved: 2026-09-09
Exact DailyMed HTML label identity and selected named sections checked. A page update is not proof that renal instructions changed.
No raw SPL XML, original XML hash or separate Drugs@FDA revision-history review was performed.
1 documented source differences / product cautions
Dose / interval guidanceOfficial-label summariesMonitoring / toxicity / cautions
Allopurinol tablets - Aurobindo indication-specific renal tables
Official label | Manually labeled selected summary
Product / population: Adults; gout initiation versus cancer-therapy hyperuricemia, not interchangeable indications.
Renal measure: Label prints eGFR in mL/min without a surface-area suffix; do not silently convert to CrCl.
Measure label: Measure not yet classified. Read the exact source wording above.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Source dates and additional notes
Source revision: 5/2024
Retrieved: 2026-09-10
For impaired-renal gout, increase by 50 mg/day every 2-4 weeks to urate response; an eGFR-specific maximum is not defined.
Renal dosing for recurrent calcium oxalate stones is not established. Pediatric renal instructions are not inferred. Review hypersensitivity, kidney function and interactions.
2 documented source differences / product cautions
Dose / interval guidanceOfficial-label summariesMonitoring / toxicity / cautions
Allopurinol for injection - exact generic IV label
Official label | Manually labeled selected summary
Product / population: Adults with cancer-therapy hyperuricemia who cannot tolerate oral therapy; IV formulation.
Renal measure: Creatinine clearance, mL/min.
Measure label: CrCl in mL/min. Read the exact source wording above.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Source dates and additional notes
Source revision: 10/2022
Retrieved: 2026-09-10
These are total daily amounts, not doses per infusion. The selected table does not establish pediatric severe-renal or dialysis dosing.
Review uric acid, renal function and interacting azathioprine/mercaptopurine therapy. This generic product label does not newly verify every ALoprim preparation detail.
2 documented source differences / product cautions
Not classified by finding typeOfficial-label summariesUnclassified / original material
Alogliptin tablets (single agent) - selected U.S. labeling
Official label | Existing source category; topic coverage may be incomplete
Product / population: Adults with type 2 diabetes; oral alogliptin single-agent tablets, not alogliptin/metformin or alogliptin/pioglitazone combinations.
Renal measure: Creatinine clearance (CrCl) in mL/min, as specified in the selected U.S. labeling.
Measure label: Measure not yet classified. Read the exact source wording above.
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Source dates and additional notes
Source revision: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05
1 documented source differences / product cautions
Dose / interval guidanceOfficial-label summariesMonitoring / toxicity / cautions
Amantadine immediate-release capsules - Alembic US label
Official label | Manually labeled selected summary
Product / population: Immediate-release 100 mg capsules; adult renal instructions. Not GOCOVRI or OSMOLEX ER.
Renal measure: Source prints indexed creatinine clearance, mL/min/1.73 m2.
Measure label: Measure not yet classified. Read the exact source wording above.
Selected source sections stored locally. Not a complete monograph or independent clinical approval.
Source dates and additional notes
Source revision: 06/2025
Retrieved: 2026-09-10
Renal accumulation has caused fatal toxicity when doses exceeded recommendations. Hemodialysis removes negligible amounts.
Monitor CNS effects, edema and orthostatic hypotension. Do not abruptly discontinue in Parkinson disease. Historical influenza indications are not a current antiviral recommendation.
Drug-level cautionThe live source uses the spelling Amantidine in its heading and URL; amantadine is retained as the searchable ingredient name. This is not a modified-release amantadine protocol.
1 documented source differences / product cautions
Pharmacokinetic observation onlyOfficial-label summariesMonitoring / toxicity / cautionsUnstudied ranges / evidence gapsPharmacokinetic observations
DailyMed / BARHEMSYS exact product label
Official label | Manually labeled selected summary
Product / population: Single-dose IV BARHEMSYS for adult postoperative nausea/vomiting; not repeated oral psychiatric treatment.
Renal measure: eGFR, mL/min/1.73 m2; studied severe group not requiring dialysis
Measure label: Indexed eGFR / GFR. Read the exact source wording above.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: 9/2022
Retrieved: 2026-09-10
Exact DailyMed HTML label identity and selected named sections checked. A page update is not proof that renal instructions changed.
No raw SPL XML, original XML hash or separate Drugs@FDA revision-history review was performed.
1 documented source differences / product cautions
Not classified by finding typeOfficial-label summariesUnclassified / original material
Amlodipine single-agent tablets - starting dose and renal statement
Official label | Existing source category; topic coverage may be incomplete
Product / population: Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal measure: No renal-function dose bands specified for this summary.
Measure label: Measure not yet classified. Read the exact source wording above.
Locally included source-specific summary. Regimen differences are not automatically resolved.
Source dates and additional notes
Source revision: Selected repackaged label updated 2022-01-21; prescribing text revised January 2017.
Retrieved: 2026-09-05
No difference note is recorded here. This does not certify agreement.
Not classified by finding typeOfficial-label summariesUnclassified / original material
Amphotericin B liposomal (AmBisome) - selected U.S. labeling
Official label | Existing source category; topic coverage may be incomplete
Product / population: Adults receiving intravenous liposomal amphotericin B, specifically AmBisome. Not interchangeable with deoxycholate, lipid-complex or other amphotericin formulations.
Renal measure: Qualitative renal/PK evidence; no label CrCl-based reduction table.
Measure label: Measure not yet classified. Read the exact source wording above.
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Source dates and additional notes
Source revision: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05
No difference note is recorded here. This does not certify agreement.
Dose / interval guidanceOfficial-label summariesDose / interval guidanceMonitoring / toxicity / cautionsUnstudied ranges / evidence gaps
KINERET - official renal dosing and indication distinction
Official label | Manually labeled selected summary
Product / population: Subcutaneous anakinra: RA versus NOMID/DIRA doses remain distinct.
Renal measure: CrCl <30 mL/min, including ESRD.
Measure label: CrCl in mL/min. Read the exact source wording above.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Source dates and additional notes
Source revision: October 2025
Retrieved: 2026-09-07
Separate DailyMed retrieval; the KINERET RX click remains failed.
1 documented source differences / product cautions
Not classified by finding typeOfficial-label summariesUnclassified / original material
Anastrozole tablets - selected U.S. labeling
Official label | Existing source category; topic coverage may be incomplete
Product / population: Postmenopausal women with the breast-cancer indications covered by the selected U.S. label; oral anastrozole tablets.
Renal measure: Qualitative renal guidance; no CrCl threshold for dose reduction.
Measure label: Measure not yet classified. Read the exact source wording above.
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Source dates and additional notes
Source revision: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05
No difference note is recorded here. This does not certify agreement.
Not classified by finding typeOfficial-label summariesUnclassified / original material
Anidulafungin (Eraxis, adults) - selected U.S. labeling
Official label | Existing source category; topic coverage may be incomplete
Product / population: Adult Candida infection treatment with intravenous anidulafungin. Pediatric doses are excluded.
Renal measure: Qualitative renal guidance, including dialysis; no CrCl adjustment table.
Measure label: Measure not yet classified. Read the exact source wording above.
Selected dosing/renal sections read; concise local summary, not full prescribing information.
Source dates and additional notes
Source revision: Label revision date not separately recorded; retrieval date is not the revision date.
Retrieved: 2026-09-05
No difference note is recorded here. This does not certify agreement.